BACKGROUND: Highly active antiretroviral therapy (HAART) has been associated with liver toxicity. The role of monitoring for liver toxicity has not been well studied in resource-limited settings (RLS). OBJECTIVES: To determine the background prevalence and incidence of liver injury and describe the associated signs and symptoms of acute hepatitis after initiating HAART; and to determine the role of liver enzyme tests in monitoring hepatotoxicity. METHODS: In this prospective study, in Mulago Hospital AIDS Clinics, we consecutively enrolled adult patients initiated on one of three first line HAART regimens [Stavudine (d4T)-Lamivudine (3TC) and nevirapine (NVP); Zidovudine (AZT)-3TC and Efavirenz (EFV) or d4T-3TC-EFV]. We monitored ALT (alanine aminotransferase) and clinical evidence of acute hepatitis at baseline, 2(nd), 6(th), 10(th) and 14(th) week of therapy. RESULTS: Two hundred and forty HIV-positive HAART- naïve patients were enrolled in the study. The baseline prevalence of transaminitis was 1.7% with an incidence of 4.2% at 14 weeks. Grade 3-4 hepatotoxicity was documented in 1.3%. Jaundice was seen in grade 2-4 ALT elevations. Being on concurrent HAART and antituberculous drugs was associated with grade 2-4 toxicity compared to those who were only on HAART [OR; 16.0 (95% CI; 2.4-104.2)]. CONCLUSIONS: Incidence of severe hepatotoxicity within three months of first-line antiretroviral therapy was low, suggesting that routine measurement of transaminases may not be necessary in all patients initiating HAART in RLS. Routine measurement may be important in following patients on HAART and concurrent TB treatment as well as those with jaundice to avoid missing hepatotoxicity.
BACKGROUND: Highly active antiretroviral therapy (HAART) has been associated with liver toxicity. The role of monitoring for liver toxicity has not been well studied in resource-limited settings (RLS). OBJECTIVES: To determine the background prevalence and incidence of liver injury and describe the associated signs and symptoms of acute hepatitis after initiating HAART; and to determine the role of liver enzyme tests in monitoring hepatotoxicity. METHODS: In this prospective study, in Mulago Hospital AIDS Clinics, we consecutively enrolled adult patients initiated on one of three first line HAART regimens [Stavudine (d4T)-Lamivudine (3TC) and nevirapine (NVP); Zidovudine (AZT)-3TC and Efavirenz (EFV) or d4T-3TC-EFV]. We monitored ALT (alanine aminotransferase) and clinical evidence of acute hepatitis at baseline, 2(nd), 6(th), 10(th) and 14(th) week of therapy. RESULTS: Two hundred and forty HIV-positive HAART- naïve patients were enrolled in the study. The baseline prevalence of transaminitis was 1.7% with an incidence of 4.2% at 14 weeks. Grade 3-4 hepatotoxicity was documented in 1.3%. Jaundice was seen in grade 2-4 ALT elevations. Being on concurrent HAART and antituberculous drugs was associated with grade 2-4 toxicity compared to those who were only on HAART [OR; 16.0 (95% CI; 2.4-104.2)]. CONCLUSIONS: Incidence of severe hepatotoxicity within three months of first-line antiretroviral therapy was low, suggesting that routine measurement of transaminases may not be necessary in all patients initiating HAART in RLS. Routine measurement may be important in following patients on HAART and concurrent TB treatment as well as those with jaundice to avoid missing hepatotoxicity.
Authors: P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas Journal: Int J STD AIDS Date: 2010-08 Impact factor: 1.359
Authors: Ian Sanne; Herve Mommeja-Marin; John Hinkle; John A Bartlett; Michael M Lederman; Gary Maartens; Charles Wakeford; Audrey Shaw; Joseph Quinn; Robert G Gish; Franck Rousseau Journal: J Infect Dis Date: 2005-02-10 Impact factor: 5.226
Authors: E Martínez; J L Blanco; J A Arnaiz; J B Pérez-Cuevas; A Mocroft; A Cruceta; M A Marcos; A Milinkovic; M A García-Viejo; J Mallolas; X Carné; A Phillips; J M Gatell Journal: AIDS Date: 2001-07-06 Impact factor: 4.177
Authors: Paul J Weidle; Samuel Malamba; Raymond Mwebaze; Catherine Sozi; Gideon Rukundo; Robert Downing; Debra Hanson; Dorothy Ochola; Peter Mugyenyi; Jonathan Mermin; Badara Samb; Eve Lackritz Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan Weel; Suzanne Jurriaans; Joep M A Lange Journal: J Infect Dis Date: 2002-06-14 Impact factor: 5.226
Authors: Derick Nii Mensah Osakunor; Christian Obirikorang; Vincent Fianu; Isaac Asare; Mavis Dakorah Journal: PLoS One Date: 2015-08-06 Impact factor: 3.240